InsidersTradesSigma
申报总数
公司
▲ 买入（3 笔）
▼ 卖出（3 笔）
内部人交易记录
首席执行官已披露买入
3
已披露卖出
3
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Explore the detailed record of transactions filed by Juan Carlos JARAMILLO, 副首席执行官. Director active across 1 company, notably VALNEVA SE. In total, 7 disclosures have been published. Breakdown: 3 buys · 3 sells. Total volume traded: €104k. History available since 18 October 2024. The latest transaction was disclosed on 22 January 2026 (Cession). Regulator: AMF. All data is accessible without signup.
Companies and markets linked to Juan Carlos JARAMILLO
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报7 总计
11,800 股@ €4.407516.2% 占其流量ActionEuronext ParisISIN FR00040568512026DD1090816
82,899 股@ €2.6267.7% 占其流量Option d'achatHors plateforme de négociationISIN FR00040568512026DD1089345
23,622 股0ActionHors plateforme de négociationISIN FR00040568512025DD1075105
标准退出：2026年3月15日 (T+90)
5,274 股@ €4.46847.3% 占其流量ActionEuronext ParisISIN FR00040568512025DD1064410
9,588 股0ActionHors plateforme de négociationISIN FR00040568512025DD1063582
标准退出：2026年1月8日 (T+90)
19,176 股0ActionHors plateforme de négociationISIN FR00040568512024DD1007331
标准退出：2025年1月8日 (T+90)
10,547 股@ €2.6648.8% 占其流量ActionEuronext ParisISIN FR00040568512024DD1007338
7 条申报中的 7 条
About Juan Carlos JARAMILLO
Juan Carlos Jaramillo, MD, holds a senior executive position at Valneva SE, where he serves as Chief Medical Officer and, following the board appointment on December 20, 2023, as an Associate Managing Director / Directeur général délégué. He joined Valneva in October 2020 as a member of the Management Board, bringing substantial international experience in medical affairs, clinical development, and market access. In a specialty vaccine company such as Valneva, his role is central to aligning scientific strategy, development priorities, and commercial readiness. Before joining Valneva, Jaramillo built a broad career in global pharmaceuticals. Valneva states that he held senior positions at Daiichi Sankyo, Grünenthal, and GlaxoSmithKline. His background spans vaccines and therapeutics, as well as global market access and pricing strategy, giving him a profile that combines medical leadership with a strong business perspective. The company also highlights his deep understanding of healthcare systems across multiple geographies, which is an important asset in international biopharma decision-making. His appointment at Valneva in 2020 came at a time when the company was advancing a number of major vaccine programs. At the time, Valneva emphasized his strong track record across a wide range of settings, therapeutic areas, and regions, as well as his multicultural leadership style. Since then, his progression to an expanded executive role reflects the company’s confidence in his leadership and his contribution to the group’s strategic development. Jaramillo’s core expertise lies at the intersection of science, strategy, and execution. He brings together clinical and medical leadership, access and pricing knowledge, and experience navigating complex regulatory and healthcare environments. For a listed vaccine company, that combination is especially valuable: it supports disciplined clinical programs, informed stakeholder engagement, and a stronger bridge between R&D and commercialization. His career therefore positions him as a key executive in Valneva’s governance and long-term growth framework.
